Copy to clipboard 
Evonik is transforming its Health Care business to maximize customer centricity and market focus. Effective April 1, 2022, the company has streamlined its operations into three new product lines: Drug Delivery & Product, Drug Substance, and Health Solutions. Each product line builds on differentiating technology platforms to meet the specific requirements of diverse healthcare markets.
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries. As part of the Nutrition & Care division, the Health Care business plays a key role in increasing the division’s share of system solutions from 20% today to more than 50% by 2030.
“This strategic transformation of our business line will unleash innovation and new service potential – for the benefit of our customers and patients. We’re proud to be the preferred development and manufacturing partner for the industry’s most innovative therapies,” says Dr. Thomas Riermeier, head of Evonik’s Health Care business line.
Under the leadership of Maximillian Yeh, the Health Solutions product line will focus on fast-growing markets. The unit brings together the biopharma solutions, medical device solutions and advanced food ingredients solutions businesses.
RESOMER is Evonik’s brand of bioresorbable polymers for use with implantable medical devices. RESOMER polymers are suitable for use across a broad range of orthopedic, vascular, wound closure and other medical device applications.
Mr. Yeh was previously responsible for the global sales organization of the Health Care business line and has more than 30 years of experience in the chemical and pharmaceutical industry.
Source: Evonik
